Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Prostate Cancer

Free Subscription 24.08.2020 1 Acta Radiol 3 AJR Am J Roentgenol 1 Am J Pathol 1 Cancer 1 Cancer Res 6 Eur Urol 2 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 1 J Natl Cancer Inst 1 J Nucl Med 2 J Urol 3 Oncogene 1 PLoS One 1 Prostate

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Radiol

1. KIM SH
   Determination of Gleason score discrepancy for risk stratification in magnetic resonance-ultrasound fusion prostate biopsy.
   Acta Radiol. 2020;61:1134-1142.
   PubMed         Abstract available
   
   

   
   AJR Am J Roentgenol

2. SCHOOTS IG, Barentsz JO, Bittencourt LK, Haider MA, et al
   PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy Naive Men with Suspected Prostate Cancer: A Narrative Review.
   AJR Am J Roentgenol. 2020 Aug 19. doi: 10.2214/AJR.20.24268.
   PubMed         Abstract available
   
   
3. SURASI DSS
   Editorial Comment on "Diagnostic accuracy of 68Ga-PSMA PET/CT for initial detection in patients with suspected prostate cancer: A systematic review and meta-analysis".
   AJR Am J Roentgenol. 2020 Aug 19. doi: 10.2214/AJR.20.24405.
   PubMed        
   
   
4. WOO S, Vargas HA
   Commentary on "Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study".
   AJR Am J Roentgenol. 2020 Jul 29. doi: 10.2214/AJR.20.23666.
   PubMed        
   
   

   
   Am J Pathol

5. CHUNG WC, Zhou X, Atfi A, Xu K, et al
   Pik3cg is a potential therapeutic target in androgen receptor-indifferent metastatic prostate cancer.
   Am J Pathol. 2020 Aug 14. pii: S0002-9440(20)30371.
   PubMed         Abstract available
   
   

   
   Cancer

6. JOSHI SS, Filson CP
   Long-term consequences of the USPSTF Grade D recommendation for prostate-specific antigen screening.
   Cancer. 2020;126:694-696.
   PubMed        
   
   

   
   Cancer Res

7. SCHONHOFT JD, Zhao JL, Jendrisak A, Carbone EA, et al
   Morphology-predicted large scale transition number in circulating tumor cells identifies a chromosomal instability biomarker associated with poor outcome in castration-resistant prostate cancer.
   Cancer Res. 2020 Aug 19. pii: 0008-5472.CAN-20-1216.
   PubMed         Abstract available
   
   

   
   Eur Urol

8. SCHAID DJ, McDonnell SK, FitzGerald LM, DeRycke L, et al
   Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer.
   Eur Urol. 2020 Aug 13. pii: S0302-2838(20)30614.
   PubMed         Abstract available
   
   
9. FIZAZI K, Drake CG, Beer TM, Kwon ED, et al
   Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.
   Eur Urol. 2020 Aug 15. pii: S0302-2838(20)30604.
   PubMed         Abstract available
   
   
10. MONTORSI F, Gandaglia G, Fossati N, Salonia A, et al
    Re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.03.035.
    Eur Urol. 2020 Aug 11. pii: S0302-2838(20)30540.
    PubMed        
    
    
11. MONTORSI F, Salonia A, Briganti A
    Re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
    Eur Urol. 2020 Aug 13. pii: S0302-2838(20)30603.
    PubMed        
    
    
12. DI LORENZO G, Autorino R
    Androgen Receptor Signaling Inhibitors in Nonmetastatic Castration-resistant Prostate Cancer and Risk of Cardiovascular Toxicity: All That Glitters Isn't Gold.
    Eur Urol. 2020 Aug 13. pii: S0302-2838(20)30612.
    PubMed         Abstract available
    
    
13. GANDAGLIA G, Montorsi F, Briganti A
    Reply to Jonathan Aning, Paul McCoubrie, and Jon Oxley's Letter to the Editor re: Giorgio Gandaglia, Guillaume Ploussard, Massimo Valerio, et al. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targ
    Eur Urol. 2020 Aug 13. pii: S0302-2838(20)30619.
    PubMed        
    
    

    
    Int J Radiat Oncol Biol Phys

14. 
    Erratum to: Pollack A, Chinea FM, Bossart E, Kwon D, Abramowitz MC, Lynne C, Jorda M, Marples B, Patel VN, Wu XD, Reis I, Studenski MT, Casillas J, Stoyanova R. Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Rad
    Int J Radiat Oncol Biol Phys. 2020;108:328.
    PubMed        
    
    
15. DEEK MP, Taparra K, Dao D, Chan L, et al
    Patterns of Recurrence and Modes of Progression Following Metastasis Directed Therapy in Oligometastatic Castration Sensitive Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Aug 13. pii: S0360-3016(20)34120.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

16. ABIDA W, Patnaik A, Campbell D, Shapiro J, et al
    Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
    J Clin Oncol. 2020 Aug 14:JCO2001035. doi: 10.1200/JCO.20.01035.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

17. ROBERTS AW, Eiffert S, Wulff-Burchfield EM, Dusetzina SB, et al
    Opioid use disorder and overdose in older adults with breast, colorectal, or prostate cancer.
    J Natl Cancer Inst. 2020 Aug 17. pii: 5893484. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

18. SPRUTE K, Kramer V, Koerber S, Meneses M, et al
    Diagnostic accuracy of (18)F-PSMA-1007-PET/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence.
    J Nucl Med. 2020 Aug 17. pii: jnumed.120.246363. doi: 10.2967/jnumed.120.246363.
    PubMed         Abstract available
    
    

    
    J Urol

19. HAJIRAN A, Pow-Sang J
    Re: Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study.
    J Urol. 2020;204:159.
    PubMed        
    
    
20. CADEDDU JA
    Re: Comparison of Outcomes of Salvage Robot-Assisted Laparoscopic Prostatectomy for Post-Primary Radiation vs Focal Therapy.
    J Urol. 2020;204:168.
    PubMed        
    
    

    
    Oncogene

21. SHAH K, Gagliano T, Garland L, O'Hanlon T, et al
    Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing.
    Oncogene. 2020 Aug 20. pii: 10.1038/s41388-020-01429.
    PubMed         Abstract available
    
    
22. WANG Z, Li Y, Wu D, Yu S, et al
    Correction: Nuclear receptor HNF4alpha performs a tumor suppressor function in prostate cancer via its induction of p21-driven cellular senescence.
    Oncogene. 2020 Aug 20. pii: 10.1038/s41388-020-1290.
    PubMed         Abstract available
    
    
23. SHIN SH, Kim I, Lee JE, Lee M, et al
    Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer.
    Oncogene. 2020 Aug 14. pii: 10.1038/s41388-020-01418.
    PubMed         Abstract available
    
    

    
    PLoS One

24. PAPANDRIANOS N, Papageorgiou E, Anagnostis A, Papageorgiou K, et al
    Bone metastasis classification using whole body images from prostate cancer patients based on convolutional neural networks application.
    PLoS One. 2020;15:e0237213.
    PubMed         Abstract available
    
    

    
    Prostate

25. LIU W, Hou J, Petkewicz J, Na R, et al
    Feasibility and performance of a novel probe panel to detect somatic DNA copy number alterations in clinical specimens for predicting prostate cancer progression.
    Prostate. 2020 Aug 17. doi: 10.1002/pros.24057.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: